Figures & data
Table 1. Characteristics of studies included in the meta-analysis.
Table 2. Multivariate regression analysis with interaction terms.
Berardi R, Santoni M, Rinaldi S et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small-cell lung cancer. Ann. Transl. Med. 7(20), 572 (2019). Bilgetekin I, Basal FB. Systemic immune-inflammation index is the best prognostic factor in patients with advanced stage adenocarcinoma of the lung treated with pemetrexed. J. Coll. Physicians Surg. Pak. 30(9), 933–939 (2020). Coutu BG, Johnson KC, Bhirud A et al. Systemic immune-inflammatory index association with survival in patients undergoing trimodality therapy for lung cancer. Oncology 100(5), 247–256 (2022). Delikgoz SE, Kemal Y, Karacin C et al. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. J. Med. Imaging Radiat. Oncol. 66(1), 146–157 (2022). Deng C, Zhang N, Wang Y et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (Baltimore) 98(33), e16875 (2019). Fu F, Deng C, Wen Z et al. Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small-cell lung cancer. Transl. Lung Cancer Res. 10(7), 3144–3154 (2021). Gao Y, Zhang H, Li Y et al. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small-cell lung cancer. Clin. Chim. Acta 484, 272–277 (2018). Guo D, Zhang J, Jing W et al. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncol. 14(25), 2643–2650 (2018). Guo W, Cai S, Zhang F et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small-cell lung cancer. Thorac. Cancer 10(4), 761–768 (2019). Ju Q, Huang T, Zhang Y et al. Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. Medicine (Baltimore) 100(6), e24640 (2021). Keit E, Coutu B, Zhen W et al. Systemic inflammation is associated with inferior disease control and survival in stage III non-small-cell lung cancer. Ann. Transl. Med. 9(3), 227 (2021). Li A, Mu X, He K et al. Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases. Future Oncol. 16(30), 2433–2444 (2020). Li B, Wang S, Li C et al. The kinetic changes of systemic inflammatory factors during bevacizumab treatment and its prognostic role in advanced non-small-cell lung cancer patients. J. Cancer 10(21), 5082–5089 (2019). Li H, Wang G, Zhang H et al. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations. Genes Immun. 20(6), 455–461 (2019). Li W, Qu Y, Wen F et al. Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases. Biomark Med. 15(13), 1071–1084 (2021). Li X, Hu P, Liu J et al. Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol. 16(5), 103–115 (2020). Liu J, Li S, Zhang S et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J. Clin. Lab. Anal. 33(8), e22964 (2019). Shen YJ, Qian LQ, Ding ZP et al. Prognostic value of inflammatory biomarkers in patients with stage I lung adenocarcinoma treated with surgical dissection. Front Oncol. 11, 711206 (2021). Takeda T, Yamada T, Tanimura K et al. Prognostic markers of survival among japanese patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving first-line alectinib. Diagnostics (Basel) 11(12), 2170 (2021). Tomita M, Ayabe T, Maeda R et al. Systemic immune-inflammation index predicts survival of patients after curative resection for non-small-cell lung cancer. In Vivo 32(3), 663–667 (2018). Tong YS, Tan J, Zhou XL et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small-cell lung cancer. J. Transl. Med. 15(1), 221 (2017). Watanabe K, Noma D, Masuda H et al. Preoperative inflammation-based scores predict early recurrence after lung cancer resection. J. Thorac. Dis. 13(5), 2812–2823 (2021). Xu S, Cao S, Yu Y. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis. J. Cancer Res. Ther. 17(7), 1636–1642 (2021). Yan X, Li G. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small-cell lung cancer. Biosci. Rep. 40(3), BSR20200352 (2020). Zhang Y, Chen Z, Jin F et al. The value of the systemic immune-inflammation index in predicting survival outcomes in patients with brain metastases of non-small-cell lung cancer treated with stereotactic radiotherapy. Mediators Inflamm. 2021, 2910892 (2021).